Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381810 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
A Phase 3 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT00381810 is a Phase 3 study that was terminated before completion, run by Genentech. The registered enrollment target is 31 participants.
The verdict
NCT00381810, a Phase 3 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months over the course of 1 year with reassessment of response at 12 months. This study is open to participants previously enrolled in Genentech Study U2971g only.
Interventions
- DRUG Acetaminophen
- DRUG Rituximab
- DRUG Methylprednisolone
- DRUG Diphenhydramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-06-22 |
| Est. Completion | 2012-02-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381810
The ClinicalTrials.gov registry entry for NCT00381810 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Acetaminophen is the first listed.
NCT00381810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381810 about?
NCT00381810 is a clinical study titled "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus". This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months over the course of 1 year with reassessment of response at 12 months. This study is open to participants previously enrol...
What is the current status of trial NCT00381810?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2006-06-22. Estimated completion is 2012-02-29.
What interventions are being tested in trial NCT00381810?
The interventions under investigation include: Acetaminophen (DRUG), Rituximab (DRUG), Methylprednisolone (DRUG), Diphenhydramine (DRUG).
Who is sponsoring clinical trial NCT00381810?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.